Visual Analysis of the Research Status of Active Surveillance of Drug Safety in China Based on CiteSpace

Abstract

Objective To analyze the current research status and development trend of active surveillance of drug safety in China, and to provide reference and suggestions for future research. Methods Using bibliometric methods and with the help of the CiteSpace 6.1.R6, the literature on active surveillance of drug safety in CNKI from 2010 to 2022 was visualized and analyzed in terms of authors, institutions and keywords. Results and Conclusion The research on active surveillance of drug safety in China started late and is in a stable development period. Some Chinese scholars have done more work on active surveillance of drug safety. Additionally, a number of institutions have published some articles and surveillance objects, surveillance methods, and surveillance results are the main research content. However, the cross-institutional cooperation is not close. The traditional Chinese medicine injection, centralized surveillance, and automatic surveillance are the hot spots of research. It is the latest research frontier to use the Chinese hospital pharmacovigilance system to actively monitor drug safety. At present, the research related to active surveillance of drug safety in China is still in the early stage, and more in-depth research is needed to follow up.

Keywords

drug safety / active surveillance / CiteSpace / research status / visual analysis

References

[1] Yang Yu, Zhan Siyan. Analysis of necessity and feasibility in studies of post-marketing drug safety active surveillance based on big data[J]. Chinese Journal of Pharmacoepidemiology, 2016, 25 (7): 401-404+413.

[2] Yang Li, Tian Lijuan, Luo Gang. Comparative research and enlightenment on active post-marketing drug safety surveillance systems from the global perspective[J]. Science and Technology Management Research, 2017, 37 (7): 182-190.

[3] Wang Jiao, Gu Xifang. Exploration of centralized monitoring model for ADE/ADR in Chinese medicine injection[J]. Asia-Pacific Traditional Medicine, 2021, 17 (9): 215-218.

[4] Liu Shixian, Wang Kaixuan, Dou Lei, et al. Bibliometric and visualization analysis of pharmacoeconomic evaluation research at home and abroad[J]. Chinese Journal of Hospital Pharmacy, 2021, 41 (22): 2368-2374+2384.

[5] Xiao Misu, Zhang Jianping, Yang Quanjun, et al. Analysis of the current situation of research on comprehensive evaluation of drugs in China based on CiteSpace[J]. China Pharmacy, 2022, 33 (8): 911-916.

[6] Wu Wenyu, Wei Fenfang, Wu Jianru, et al. Visual analysis of pharmacovigilance-related literature on Web of Science in the last 30 years using CiteSpace[J]. Journal of Guangdong Pharmaceutical University, 2022, 38 (6): 35-44.

[7] Chen Chao, Guo Daihong, Xue Wanguo, et al. Development of alarming system to actively monitor and assess the adverse drug events in hospitalized patients[J]. Chinese Journal of Pharmacovigilance, 2013, 10 (7): 411-414+418.

[8] Wang Xiaoyu, Guo Daihong, Xu Yuanjie. Study on automatic monitoring module of inpatient drug-induced allergy based on text categorization technology[J]. China Drug Application and Monitoring, 2016, 13 (2): 117-120.

[9] Zhang Bo, Guo Daihong, Guo Haili, et al. Clinical characteristics and influencing factors of 14 287 hospitalized patients with acute kidney injury caused by cisplatin for injection[J]. Chinese Journal of Clinical Pharmacy, 2022, 31 (2): 93-97.

[10] Yao Chong, Liu Dongjie, Guo Daihong, et al. The development on active surveillance and assessment system-II of adverse drug events[J]. China Drug Application and Monitoring, 2020, 17 (6): 387-391.

[11] Liao Xing, Yu Dandan, Xie Yanming, et al. Post-marketing safety surveillance of Diemailing Kudiezi injection: Real-world study in 30 233 cases[J]. Chinese Journal of Chinese Materia Medica, 2017, 42 (15): 2857-2863.

[12] Wang Zhifei, Yu Jinyang, Xie Yanming. Clinical safety intensive hospital monitoring on Shenfu injection with 30 106 cases[J]. Chinese Journal of Chinese Materia Medica, 2017, 42 (15): 2871-2876.

[13] Lai Yuanyuan, Fang Bangjiang, Liu Jian, et al. Safety report of 30 013 Yueanxin Kudiezi injection based on centralized hospital monitoring[J]. World Chinese Medicine, 2020, 15 (1): 30-34.

[14] Zhang Junhua, Ren Jingtian, Hu Jingqing, et al. Expert consensus on the design and implementation of centralized clinical safety monitoring studies of Chinese medicine injectables[J]. Chinese Journal of Chinese Materia Medica, 2017, 42 (1): 6-9.

[15] Liu Zhi, Zheng Wenke, Zhang Junhua, et al. Content and key points of data management of hospital centralized monitoring study on the safety of Chinese medicine injections[J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, 2016, 18 (12): 2083-2087.

[16] Wang Hui, Zhang Junhua, Zheng Wenke, et al. Reflections on ethics-related issues of hospital-centered monitoring studies on the safety of Chinese medicine injectables[J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, 2017, 19 (1): 161-165.

[17] Xia Shujie, Yang Zhaoyang, Lin Xuejian, et al. Application of data mining in diagnosis of traditional Chinese medicine based on bibliometric analysis[J]. Tianjin Chinese Medicine, 2021, 38 (2): 142-151.

[18] Li Xuelin, Tang Jinfa, Meng Fei, et al. Study on 10 409 cases of post-marketing safety Danhong injection centralized monitoring of hospital[J]. Chinese Journal of Chinese Materia Medica, 2011, 36 (20): 2783-2785.

[19] Kang Along, Zhang Xian, Huang Liming, et al. Safety evaluation of 700 cases of Danhong injection in its clinical application by active centralized monitoring[J]. Chinese Journal of Pharmacovigilance, 2012, 9 (6): 360-362.

[20] Ren Jingtian, Guo Xiaoxin, Cheng Gang. Current s tatus and recommendations of the work of focused drug surveillance[J]. Chinese Journal of Pharmacoepidemiology, 2014, 23 (10): 602-607+611.

[21] Xie Minjiang, He Huping, Huang Bihui, et al. Centralized monitoring of clinical safety of Yunnan Baiyao capsules in Sichuan[J]. Chinese Journal of New Drugs, 2019, 28 (6): 719-725.

[22] Lv Qiuxia, Cao Yujing, Li Yang, et al. A report on the centralized monitoring study of clinical safety of Yunnan Baiyao capsules in Henan[J]. China Modern Drug Application, 2018, 12 (21): 211-215.

[23] Yunnan Baiyao. The centralized clinical safety monitoring project of Yunnan Baiyao capsules was successfully concluded[EB/OL]. (2016-11-12)[2023-01-05]. http://www.yunnanbaiyao.com.cn/view/ynbyPc/1/92/view/1868.html.

[24] Yuan Xingdong, Xu Yuming, Zhou Juan, et al. Influence of Chinese hospital pharmacovigilance system on quality of ADR reports in 2 hospitals[J]. Chinese Journal of Pharmacovigilance, 2021, 18 (2): 138-140.

[25] Mo Kai, Nong Li, Cao Wen, et al. Research on adverse drug reaction monitoring based on Chinese hospital pharmacovigilance system[J]. Chinese Journal of Pharmacovigilance, 2020, 17 (10): 672-675.

[26] Han Haiyan, Liu Qiaozhen, Ji Lihong. Effect of Chinese hospital pharmacovigilance system on the reporting of adverse drug reactions in a hospital[J]. Chinese Journal of Drug Abuse Prevention and Control, 2022, 28 (6): 707-710.